Evaluation of Serum Biomarkers in Patients with Sarcoidosis: Can Visfatin Be a New Biomarker for Sarcoidosis?


Tanriverdi E., Iliaz S., Cortuk M. , Turan D., Chousein E. G. U. , Gul S., ...Daha Fazla

TURKISH THORACIC JOURNAL, cilt.21, ss.145-149, 2020 (ESCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 21 Konu: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5152/turkthoracj.2019.180112
  • Dergi Adı: TURKISH THORACIC JOURNAL
  • Sayfa Sayıları: ss.145-149

Özet

OBJECTIVES: Sarcoidosis is a chronic systemic inflammatory disease that affects multiple organ systems. The role of biomarkers in the diagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue-mediated inflammation in the pathogenesis of inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine that has been studied for several inflammatory diseases such as diabetes mellitus, obesity, and metabolic syndrome. We aimed to assess serum visfatin levels in sarcoidosis and its relationship with other markers of inflammation such as C-reactive protein (CRP), angiotensin-converting enzyme (ACE) and erythrocyte sedimentation rate (ESR).